Pfizer, Santaris Expand RNA Pact

Santaris Pharma and Pfizer have expanded their collaboration for the development and commercialization of RNA-targeted medicines using Santaris Pharma’s Locked Nucleic Acid (LNA) drug platform.

Santaris Pharma and Pfizer have expanded their collaboration for the development and commercialization of RNA-targeted medicines using Santaris Pharma’s Locked Nucleic Acid (LNA) drug platform. Santaris will receive a $14 million payment from Pfizer for access to its LNA technology and is eligible to receive milestone payments of as much as $600 million and royalties on sales of products for as many as 10 new RNA targets selected by Pfizer.

The original collaboration began in January 2009 between Santaris and Wyeth, which was acquired by Pfizer. Pfizer has advanced several programs under the original collaboration and has reached a number of early milestones.